

ASX: CVB

13 February 2024

Securities released from escrow

CurveBeam AI Limited (ASX:CVB) (the **Company**) hereby advises pursuant to ASX Listing Rule 3.10A that the following securities are due to be released from ASX restrictions as outlined below:

Release Date	ASX Ref	Class of Securities	Number
21 February 2024	CVBAE	Shares	3,544,391
23 February 2024	CVBAF	Shares	9,669,464
23 February 2024	CVBAJ	Options (noteholder options)	5,371,923

The Company will issue an 'Appendix 2A – Application for Quotation of Securities' in respect of the Shares on or soon after the release date.

Release approved by the Board

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au